Related Experiment Videos

Glycogen storage disease type Ia: frequency and clinical course in Turkish children

I N Saltik1, H Ozen, G Ciliv

  • 1Division of Pediatric Gastroenterology, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Insights

Glycogen storage disease type Ia is common in Turkish children with liver issues. This study details its clinical features, high prevalence of hypertriglyceridemia, and frequent microalbuminuria.

Area of Science:

  • Pediatrics
  • Metabolic Disorders
  • Hepatology

Background:

  • Glycogen storage disease (GSD) encompasses various inherited metabolic disorders.
  • GSD type Ia is a significant subtype, often presenting with prominent liver involvement.
  • Understanding its epidemiology and clinical spectrum in specific populations is crucial for diagnosis and management.

Purpose of the Study:

  • To determine the relative frequency of GSD type Ia in Turkish children with liver involvement.
  • To characterize the clinical and laboratory findings, and prognosis of GSD type Ia in this cohort.
  • To compare findings with existing international reports.

Main Methods:

  • Retrospective analysis of 100 GSD patients with liver involvement diagnosed between 1980 and 1998.
  • Documentation of clinical data, routine laboratory tests, urine albumin and calcium excretion, and plasma biotinidase activity.
  • Histopathological examination of liver biopsies.

Main Results:

  • GSD type Ia accounted for 45% of GSD cases with liver involvement.
  • Diagnosis typically occurred before age 2, with hepatomegaly and abdominal protrusion as common findings.
  • Elevated plasma biotinidase activity, hypertriglyceridemia, and hypertransaminasemia were near-universal; microalbuminuria was frequent (52.8%).
  • Liver histology showed high rates of fibrosis and steatosis.

Conclusions:

  • The prevalence of GSD type Ia in Turkish children with liver involvement is higher than previously reported.
  • Clinical presentation includes significant metabolic derangements and frequent microalbuminuria.
  • Long-term management requires ongoing monitoring for metabolic complications and growth retardation.

Related Concept Videos